
Please try another search
(Reuters) -Spectrum Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration (FDA) declined to approve its experimental lung cancer drug due to inadequate data, prompting the drugmaker to cut jobs.
The company said it will no longer focus on developing the drug, poziotinib, for treating non-small cell lung cancer (NSCLC) with a rare genetic mutation that affects 2%-4% of the cancer patients. It will instead explore strategic alternatives for it, such as partnerships with other drugmakers.
Spectrum's (NASDAQ:SPPI) shares fell 13.9% to 37 cents in premarket trading. They have fallen 42.5% since an expert panel to the FDA recommended against the drug's approval in September.
The panel of independent experts had raised concerns over the efficacy of the treatment compared to drugs for NSCLC without mutation such as Daiichi Sankyo and AstraZeneca (NASDAQ:AZN)'s Enhertu.
Nevada-based Spectrum said it will cut 75% of its research and development workforce and focus on its other cancer drug, Rolvedon. It had 164 employees as of Dec. 31, 2021.
Spectrum is working to shore up capital, through cost cuts, to support a wider launch for Rolvedon, which treats patients with chemotherapy-induced infections caused due to low levels of infection-fighting cells in the body.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.